Cogstate Appoints New Director Darryl Inns With No Initial Equity Holdings

The latest announcement is out from Cogstate Ltd ( (AU:CGS) ).

Cogstate Limited has announced the appointment of Darryl Inns as a director of the company, effective 1 May 2026, in a regulatory filing to the ASX. The filing notes that Inns currently holds no relevant interests in Cogstate securities and has no disclosed interests in contracts relating to the company, indicating a starting position without equity or contractual ties as he joins the board.

This appointment signals an evolution in Cogstate’s board composition and governance structure, though the company has not provided further detail on Inns’ background or strategic role. Stakeholders will be watching for subsequent disclosures on his contributions and any potential future alignment of incentives through securities or contractual arrangements as his tenure progresses.

The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.

More about Cogstate Ltd

Cogstate Limited is an Australian-listed company operating in the healthcare and life sciences sector, with a focus on cognitive assessment technologies. The company provides scientifically validated tools and services used in clinical research, healthcare, and related fields to measure and monitor cognitive performance across various applications.

Average Trading Volume: 139,572

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$412.1M

For an in-depth examination of CGS stock, go to TipRanks’ Overview page.